Bindwell
-78%
est. 2Y upside i
Bindwell is building neural networks to replace an entire wet lab. Their wet lab in San Carlos conducts high-throughput assays that generate training data for our models. This approach—scaling computation and data rather than relying on manual design—is the fastest path to developing new pesticides and follows the teachings of Richard Sutton's The Bitter Lesson.
Rank
#1116
Sector
AgTech, Biotechnology, Artificial Intelligence
Est. Liquidity
~6Y
Data Quality
Data: MediumBindwell is an early-stage AgTech company with a strong competitive moat in AI-driven pesticide discovery, addressing a large market with significant unmet needs.
Last updated: March 10, 2026
Bindwell successfully develops and licenses multiple highly effective and safer pesticide molecules to major agrochemical firms, demonstrating superior efficacy and faster time-to-market. Key partnerships are secured, and the company's AI platform becomes an industry standard for novel molecule discovery, leading to a Series B or C valuation of $105M+ by 2028, reflecting its strong IP portfolio and validated pipeline.
Bindwell validates its AI platform with initial promising pesticide candidates and secures its first licensing agreement, demonstrating the commercial viability of its model. Progress is steady but regulatory timelines and capital needs temper rapid valuation growth, leading to a Series A or B valuation of $52.5M by 2028, in line with early-stage biotech/agtech growth.
Bindwell faces significant challenges in biological validation or regulatory approval, or incumbent agrochemical companies' internal AI efforts (e.g., Bayer's CropKey, Syngenta's partnerships) prove too dominant, limiting Bindwell's market penetration or negotiating power. This leads to a down round or failure to secure subsequent funding, resulting in a valuation of $6M or less, effectively wiping out most common stock value.
Preference Stack Risk
highInvestors hold $6M in liquidation preferences, representing 20% of the estimated $30M post-money valuation. In an exit at or below $6M, common stock holders would receive little to nothing.
Dilution Risk
highAs a seed-stage company, Bindwell will require several more funding rounds (Series A, B, C, etc.) to bring products to market, leading to significant future dilution for common stock holders.
Secondary Liquidity
noneThere is currently no active secondary market or tender offers for Bindwell's shares due to its early stage.
Questions to Ask at the Interview
Strategic questions based on Bindwell's data — designed to show you've done your homework.
- 1
“Given the high capital intensity and regulatory hurdles in pesticide development, how does Bindwell plan to manage its burn rate and secure subsequent funding rounds to reach commercialization, especially considering the long timelines for regulatory approval?”
- 2
“Bindwell's strategy is to license IP to major agrochemical companies. How do you envision these partnerships evolving, and what measures are in place to ensure Bindwell retains a strong negotiating position and fair value for its proprietary molecules against large incumbents who are also developing internal AI capabilities?”
- 3
“As an early-stage employee, what is the company's philosophy on equity refreshers, and what is the anticipated timeline for potential liquidity events (e.g., Series B, C, or an eventual acquisition/IPO) for common stock holders?”
Community
Valuation Sentiment
Our model estimates -78% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.